BCL2L1 and melanoma: Downregulation of BCL-XL in MXL90 cells by specific siRNA (Fig. 3b) or by BCL-XL inhibitor WEHI-539 (Fig. 3c), resulted in serious impairment of VM in BCL-XL overexpressing melanoma cells, when compared to control cells.